Merck blood clot drug in limbo after mixed results

.

Merck blood clot drug in limbo after mixed results

On Saturday, drug-maker Merck & Co provided details about the last month-announced results of the tests of its experimental blood thinner `vorapaxar', revealing that despite the impressive effectiveness of the blood clot drug in bringing about a significant reduction in cardio vascular incidents in heart patients, worrisome bleeding was also witnessed in people who had suffered a stroke.

According to Merck, while the experimental drug, when combined with standard care, proved effective in bringing down the instances of cardio vascular events in heart patients, it also led to increased bleeding in some patients.

When Merck presented limited data from the study in February this year, the company had said that vorapaxar was proving to be an advantageous drug for heart patients. However, the drug-maker has now revealed that patients who had been administered vorapaxar were also experiencing excessive bleeding.

The Merck revelation, based on the results of the biggest heart-drug studies conducted thus far, implies that the vorapaxar blood clot preventer has shown mixed results; and has thus led to concerns whether the drug-maker will go ahead and seek regulatory approval for the drug.

Noting that the vorapaxar trial shows that there is "clearly a tradeoff here between the protective benefit and the risk of bleeding," Dr. David Morrow - who is a cardiologist from Brigham & Women's Hospital in Boston, and the leader of the trial - said: "Should the drug be approved, he said the challenge for doctors would be to withhold it from patients at likely higher bleeding risk."


Latest News

Target Feels Progress Lies Ahead But Trims Its Outlook For the Year
Bank of America to Settle Matters With Close to $17 Billon
Medical Device Tax to Support Obamacare Is Not Collecting as Much Cash as was Ex
Standard Chartered to Pay$300 Mln Penalty By Order of New York Regulators
In July Construction of  New Homes Grow to Eight Month High
Shares of Apple Hit a Record High Before Its New iPhone 6 Arrives
Google: Its Growth and Stature
A Survey Says 36% of Americans Have No Savings for Post Retirement Years
Former Co -owners and Two Employees of Rancho Feeding Corp. Charged with Felonie
Audit Report Says Illinois Overdrew Money From Federal Medicaid
Slack in Demands Slide the Price of Homes in China
Data breach in Jewel-Osco Stores Discovered